Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - Vojnosanitetski pregled, 2010 - doiserbia.nb.rs
Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against
the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase has …
被引用次数：4 相关文章
[PDF] semanticscholar.org

[PDF][PDF] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - pdfs.semanticscholar.org
Abstract Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity
against the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase …
[PDF] mod.gov.rs

[PDF][PDF] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - ВОЈНОСАНИТЕТСКИ …, 2010 - vma.mod.gov.rs
Abstract Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity
against the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase …

Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.

I Cojbasić, L Macukanović-Golubović - Vojnosanitetski Pregled, 2010 - europepmc.org
Methods A total of 21 patients were treated and observed from July 2006 to December 2008.
The median time from CML diagnosis was no more than 12 months, so all the patients …

Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Cojbasić… - Vojnosanitetski …, 2010 - pubmed.ncbi.nlm.nih.gov
Background/aim Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against
the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has …
[PDF] archive.org

[PDF][PDF] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - scholar.archive.org
Abstract Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity
against the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase …
[PDF] nb.rs

[PDF][PDF] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - doiserbia.nb.rs
Abstract Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity
against the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase …
[PDF] mod.gov.rs

[PDF][PDF] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - ВОЈНОСАНИТЕТСКИ …, 2010 - vma.mod.gov.rs
Abstract Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity
against the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase …
[PDF] core.ac.uk

[PDF][PDF] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - core.ac.uk
Abstract Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity
against the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase …
[PDF] mod.gov.rs

[PDF][PDF] Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience

I Ćojbašić, L Mačukanović-Golubović - ВОЈНОСАНИТЕТСКИ …, 2010 - vsp.mod.gov.rs
Abstract Background/Aim. Imatinib mesylate, a tyrosine kinase inhibitor with specific activity
against the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) tyrosine kinase …